While low TIL numbers, poor differentiation, and lower TMB most likely contribute to the more aggressive behavior of EB-SCCs, the high expression of PD-L1, IDO, and PD-1 in tumor cells and their TMEs represents therapeutic targets. The gene discussed is PDCD1; the disease is neoplasm.